Danish company is battling with Pfizer for US biotech as they seek edge in growing market for weight-loss drugs ...

Danish company vies with Pfizer for control of US biotech as they seek edge in growing market for weight-loss drugs ...

The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...

A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 ...

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment ...

The battle for obesity drug maker Metsera has escalated into a high-stakes bidding war between two pharmaceutical giants, ...

NEW YORK () -Novo ​Nordisk CEO Mike ‌Doustdar said during a White House ‌event on Thursday that the company's bid for obesity ...

Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera: The antitrust ...

Pfizer and Novo Nordisk’s bidding war for the weight loss drugmaker Metsera is intensifying. Five updates: 1. Pfizer matched Novo Nordisk’s $10 billion bid for the biotech firm Nov. 5, one day after ...

The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk ...

Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare ...